Cannabis, Anxiety, and PTSD: Evidence and Limits

💊 Medical Cannabis Science & Research
, , ,
1

Cannabis and anxiety affect each other in both directions, and the effect depends on dose. The THC that eases anxiety at low doses can trigger panic attacks at high doses. CBD has a better-tolerated profile, but its controlled trials give mixed results. In PTSD, the most important controlled trial of smoked cannabis found no difference from placebo. None of this yet justifies clinical endorsement without major caveats.

Introduction

Anxiety disorders are among the most common psychiatric conditions worldwide. Post-traumatic stress disorder (PTSD) is one of the most disabling and treatment-resistant diagnoses on the anxiety spectrum. Patients often name cannabis as something that helps with both, and researchers are studying it more and more.

The idea is easy to see. Cannabinoid receptors are dense in the amygdala, hippocampus and prefrontal cortex, the regions that handle fear, memory and emotional regulation. Endocannabinoid signalling also shapes how fear memories are extinguished and how the body responds to stress. The mechanisms are covered in detail in topic 1306. Here we focus on what the clinical evidence shows.

That evidence is more complicated than the theory. The THC dose-response for anxiety is biphasic and differs from person to person. CBD trials point in different directions. The PTSD trial data are thin and include an important negative result. Cannabis use disorder and anxiety disorders also overlap heavily, which raises questions about cause and effect that observational research has not settled.

Section 1: The Biphasic Dose-Response — THC and Anxiety

One of the most clinically important ideas in cannabis pharmacology is the biphasic dose-response for anxiety. At low doses THC tends to reduce anxiety. At higher doses the same compound reliably increases it, sometimes with paranoia and, in predisposed people, full panic attacks.

Stoner (2017) reviewed this pattern in a report from the Alcohol and Drug Abuse Institute at the University of Washington, drawing on experimental and clinical literature. The report found the biphasic pattern consistent across laboratory studies that gave controlled THC doses: participants reported less anxiety at low doses and more anxiety at higher doses. (Evidence level: narrative review of experimental and observational data)

Several individual factors affect where a person falls on this curve:

  • Baseline anxiety level: People with existing anxiety disorders are more likely than non-anxious controls to feel more anxious at lower doses.
  • THC naivety: People new to cannabis are much more susceptible to THC-induced anxiety than experienced users with established tolerance.
  • Genetic variation: Variants in the COMT gene (catechol-O-methyltransferase), which regulates dopamine in the prefrontal cortex, appear to modulate susceptibility to cannabis-related psychotic and anxiety-inducing effects.
  • Setting and expectations: The setting, the person’s expectations and how safe they feel strongly influence the acute anxiety response to THC.

Clinical implication: For people with anxiety disorders, high-THC products carry a real risk of making symptoms worse rather than better. The advice to “start low, go slow” has a genuine pharmacological basis and is often given too little weight. Dosing principles are covered in the forum’s dosing guide (topic 1312).

Section 2: CBD and Anxiety — Promising but Mixed

Cannabidiol behaves quite differently from THC. It does not produce psychosis-like effects, it has not been shown to increase anxiety at the doses studied, and some controlled studies show it reducing anxiety. General CBD pharmacology is covered in topic 1327. This section covers only the anxiety trials.

  • Narrative review: Blessing et al. (2015, Neurotherapeutics) found consistent anti-anxiety effects in preclinical models and supportive human experimental data. They cautioned that controlled trials in patients with diagnosed anxiety disorders were limited. (Evidence level: narrative review)
  • Single-dose challenge: Bergamaschi et al. (2011, Neuropsychopharmacology) gave one oral dose of CBD before a simulated public-speaking test to treatment-naïve patients with social anxiety disorder. CBD reduced anxiety compared with placebo. (Evidence level: randomised, double-blind, placebo-controlled; single dose)
  • Repeated dosing in social anxiety: Masataka (2019, Frontiers in Psychology) randomised 37 Japanese 18–19-year-olds with social anxiety disorder and avoidant personality disorder to 300 mg/day CBD (n = 17) or placebo (n = 20) for four weeks. Scores on the Fear of Negative Evaluation Questionnaire and the Liebowitz Social Anxiety Scale fell significantly with CBD. (Evidence level: small double-blind RCT; narrow population)
  • Treatment-resistant anxiety, open-label: Berger et al. (2022, Journal of Clinical Psychiatry) gave add-on CBD, titrated up to 800 mg/day for 12 weeks, to 31 people aged 12–25 whose anxiety had not responded to CBT and/or antidepressants. Self-rated anxiety (OASIS) fell by about 43%. Adverse events, mostly mild (fatigue, low mood, hot flushes or chills), occurred in 25 of 31 participants. There was no control group, and placebo response is large in anxiety research, so the authors themselves call for RCTs. (Evidence level: open-label, single-arm)
  • CBD plus exposure therapy, negative: Kwee et al. (2022, European Neuropsychopharmacology) randomised treatment-refractory patients with social anxiety disorder or panic disorder with agoraphobia to 300 mg CBD (n = 39) or placebo (n = 41) alongside eight weekly exposure-therapy sessions. Fear Questionnaire scores did not differ between CBD and placebo. (Evidence level: double-blind RCT; null result)

Overall, CBD shows a reasonably consistent signal in acute and short-term social-anxiety studies. Longer-term and treatment-resistant data are either uncontrolled or negative, and dosing protocols vary widely.

Section 3: PTSD — The Short Version

PTSD is analysed in full in the forum’s dedicated article on the Bonn-Miller trial. The essentials are these. The biological rationale rests on the endocannabinoid system’s role in fear extinction and on a PET study by Neumeister et al. (2013, Molecular Psychiatry). That study found elevated CB1 receptor availability together with reduced peripheral anandamide in people with PTSD compared with trauma-exposed and healthy controls. This pattern suggests altered endocannabinoid signalling, possibly a compensatory increase in receptors, not a simple receptor “deficiency”. It also does not show that adding a CB1 agonist will correct anything. Controlled clinical data exist mainly for nabilone, a synthetic THC analogue rather than cannabis: a small crossover RCT in 10 Canadian military personnel reduced nightmares (Jetly et al., 2015), following an open-label clinical audit of nabilone in 47 patients with treatment-resistant nightmares (Fraser, 2009). For smoked cannabis, the key randomised, placebo-controlled trial is Bonn-Miller et al. (2021, PLoS One). It randomised 80 US military veterans to three weeks of high-THC, high-CBD, THC+CBD or placebo cannabis and found no significant difference from placebo in PTSD severity; every group, including placebo, improved. Registry studies that report benefit are prone to self-selection, because people who do badly tend to stop using. Cannabis therefore remains an unvalidated adjunct in PTSD.

Section 4: Specific Anxiety Disorder Subtypes

Anxiety disorders are diagnostically distinct conditions, and the evidence does not apply equally to all of them.

Generalized Anxiety Disorder (GAD)

GAD is the most common anxiety disorder but one of the least studied in relation to cannabis. We did not find a completed, published placebo-controlled trial of CBD or cannabis that specifically enrolled GAD patients. This may change, and readers should check trial registries for current studies. In self-report surveys, high-THC use in GAD populations is associated with worse chronic anxiety. (Evidence level: observational)

Social Anxiety Disorder (SAD)

Social anxiety has the most direct CBD evidence: the Bergamaschi (2011) single-dose challenge and the Masataka (2019) four-week RCT, both positive. The Kwee (2022) trial, however, found that CBD did not improve the results of exposure therapy in treatment-refractory patients. Small, short and population-specific trials do not yet show that CBD reduces SAD severity in routine practice. (Evidence level: small RCTs; mixed)

Panic Disorder

High-THC cannabis is a recognised trigger of panic attacks in susceptible people and may increase the frequency of spontaneous attacks. This is one of the clearer reasons for caution among the subtypes. The only controlled CBD data we found that include panic disorder (Kwee 2022, as an add-on to exposure therapy) were negative. We found no controlled trials of THC-containing cannabis for panic disorder. (Evidence level: observational; one negative CBD RCT)

Specific Phobia and OCD

There is little or no controlled evidence for cannabis in specific phobia or obsessive-compulsive disorder. Animal models suggest the endocannabinoid system plays a role in compulsive behaviour, but this has not translated into clinical evidence.

Section 5: Risks and Adverse Effects

Anxiety Exacerbation and Panic Attacks

At high enough doses, high-THC cannabis reliably causes anxiety and paranoia in susceptible people. This is a predictable effect, not a rare side effect. Emergency departments regularly see cannabis-precipitated panic, particularly with high-potency products and edibles, where delayed onset leads people to take too much by accident. For anyone with an anxiety-spectrum condition, starting high-THC products carries a real risk of making the condition worse.

Psychosis Risk

In people with a personal or family history of psychosis or schizophrenia-spectrum disorders, cannabis use, especially of high-potency THC products, is associated with earlier onset and greater severity of psychotic symptoms. A meta-analysis by Marconi et al. (2016, Schizophrenia Bulletin) found a dose-response relationship: the more frequent the use and the more potent the product, the greater the psychosis risk. (Evidence level: meta-analysis of epidemiological studies) This is why psychosis screening matters before anyone with a psychiatric condition starts cannabis.

Cannabis Use and Anxiety: The Causation Question

Anxiety disorders are more common among cannabis users, particularly heavy, long-term users. Three explanations compete:

Hypothesis 1 — Cannabis causes anxiety: Regular high-THC use changes the endocannabinoid system in ways that raise baseline anxiety between episodes of use. This creates a self-medication cycle that hides a worsening anxiety state.

Hypothesis 2 — Anxiety causes cannabis use: People with anxiety disorders use cannabis to self-medicate.

Hypothesis 3 — Shared vulnerability: Common factors, including genetic variation and stress-system dysregulation, predispose people to both conditions.

Mammen et al. (2018, Journal of Clinical Psychiatry) is a systematic review of prospective studies in adults who already had an anxiety or mood disorder. It included 12 studies with 11,959 participants. In 11 of them, recent cannabis use was associated with higher symptom levels over time. The review describes how existing disorders progress; it does not show that cannabis causes new anxiety diagnoses. The authors note that observational designs, sample biases and unregulated cannabis sources limit how far the findings can be taken. (Evidence level: systematic review of observational cohorts)

In practice, anxiety disorders and cannabis use disorder often occur together, the relationship probably runs both ways, and treating one without assessing the other gives worse outcomes.

Section 6: CBD vs. THC — Comparative Profiles

Dimension THC (high dose) THC (low dose) CBD
Acute anxiety ↑ Risk Modest anxiolysis ↓ in challenge studies
Psychotomimesis Yes Rare None documented
Dependence potential Yes Lower Low to minimal
PTSD / nightmare data Smoked cannabis RCT: no difference vs placebo (Bonn-Miller 2021) Nabilone (synthetic THC analogue): small crossover RCT positive for nightmares (Jetly 2015) High-CBD arm: no difference vs placebo (Bonn-Miller 2021)
RCT evidence for anxiety Limited; risk context dominant Very limited Small RCTs; mixed (positive and null)
Evidence grade Observational/mechanistic Experimental Small RCTs/open-label

For anxiety, high-CBD, low-THC products have the more favourable risk-benefit profile. Even for CBD, though, the evidence does not yet meet the bar for a guideline recommendation as a first-line or add-on anxiolytic.

Section 7: Integration with Standard Anxiety Treatments

Two separate concerns apply and should not be confused.

1. Psychotherapy (pharmacodynamic/learning concern): Exposure-based CBT works through extinction learning. In theory, cannabis use during treatment could make gains from exposure less durable by changing how memories are consolidated. This has not been tested in clinical trials. A related hope, that CBD would strengthen exposure therapy, was not supported by Kwee et al. (2022).

2. Medication (pharmacokinetic concern): CBD inhibits liver enzymes, including CYP2C19, which helps metabolise several SSRIs. CBD may therefore raise SSRI blood levels and increase their side effects. This is unrelated to extinction learning. Details are in the forum’s drug-interactions article.

Clinicians whose anxiety patients also use cannabis should ask about frequency, product type, dose, and timing relative to anxious episodes and medication. They should also be clear about what the evidence does and does not show.

Section 8: Thailand Context

  • Legal status of flower: Cannabis flower is a controlled herb under the Notification of the Ministry of Public Health Re: Controlled Herbs (Cannabis) B.E. 2568, issued 26 June 2025.
  • Prescription only: Flower may be dispensed only against a prescription on form PT 33 from an authorised practitioner. Each prescription covers no more than 30 days and is single use (no refills). Flower that is sold or exported must come from a GACP-certified cultivation site.
  • No online sales, no recreational use: Flower may not be sold or advertised online, and recreational use is not permitted.
  • 2026 changes: Two Ministerial Regulations B.E. 2569 tightened licensing: cannabis/hemp extracts (in force 26 April 2026) and controlled-herb licences No. 2 (in force 30 April 2026). They do not change the PT 33 prescription rules.
  • Cannabis Control Act: This is still a draft. The Cabinet approved it on 22 September 2026 and sent it to the House.
  • Clinical guidance: The Department of Medical Services’ Guidance on Cannabis for Medical Use (6th edition, 2024) presents cannabis products as an option where standard treatment is unsuitable, starting at a low dose and titrating slowly. Patients with anxiety or PTSD should ask the prescriber how the current edition applies to their diagnosis.

In practice, anyone in Thailand with an anxiety disorder or PTSD who is considering cannabis should go through a licensed practitioner or a PT 33 clinic. They should tell the practitioner about any psychiatric history and all current medications.

Section 9: Practical Guidance for Patients Under Medical Supervision

  1. Biphasic dose-response awareness: Patients should know that low THC doses may reduce anxiety while high doses are likely to worsen it, and that the point where one turns into the other varies between people and cannot be predicted in advance.

  2. Product selection by the prescriber: For patients treated under medical supervision, high-CBD, low-THC formulations have better evidence and lower risk for anxiety than high-THC products. The choice belongs to the treating practitioner.

  3. Start low, titrate slowly: Starting at the lowest available dose makes THC-triggered anxiety less likely. For CBD, the dose needed to reduce anxiety is not well established and may differ between single and repeated dosing (see topic 1312).

  4. Avoid high-potency THC products: Higher-potency use is associated with greater psychosis risk (Marconi 2016), and high THC doses drive anxiety. No validated percentage cut-off exists, so lower-THC options are the prudent default for anxiety-prone patients.

  5. Screen for psychosis risk: Cannabis, especially high-THC products, should be avoided by people with a personal or strong family history of psychosis. Screening should happen before cannabis is started in any psychiatric context.

  6. PTSD: Cannabis is an unvalidated adjunct. It is not a substitute for evidence-based first-line treatments such as trauma-focused cognitive behavioural therapy, EMDR, and SSRIs or SNRIs.

  7. Monitor for cannabis use disorder: In anxiety populations, self-medication can lead to dependence. Frequency of use, dose escalation, functional impairment and withdrawal symptoms should be reviewed at each visit.

Conclusion

The endocannabinoid system’s role in fear processing, extinction learning and stress regulation is a sound reason to study cannabinoids in anxiety and PTSD. The PTSD imaging data, however, show a more complex picture of altered signalling (elevated CB1 availability with low anandamide), not a simple deficiency that a CB1 agonist could correct.

The clinical evidence has not confirmed the hypothesis. For CBD in anxiety, the positive data are short-term and mostly in social anxiety, the treatment-resistant data are uncontrolled, and an exposure-therapy augmentation trial was negative. In PTSD, controlled evidence covers the synthetic analogue nabilone for nightmares in small samples, and the key placebo-controlled trial of smoked cannabis found no advantage over placebo.

This evidence supports cautious, individualised, medically supervised use in selected patients. It does not support broad therapeutic endorsement. For some patients, especially those who tolerate THC poorly, CBD-dominant treatment under medical supervision may offer modest added benefit. For others, cannabis will worsen symptoms in ways that depend on dose, vary between people, and can be prevented. The field needs adequately powered, double-blind trials with defined populations, standardised formulations and validated psychiatric outcome measures.

References

  • Bergamaschi MM et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226.
  • Berger M et al. (2022). Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial. The Journal of Clinical Psychiatry, 83(5), 21m14130.
  • Blessing EM et al. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825–836.
  • Bonn-Miller MO et al. (2021). The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLoS One, 16(3), e0246990.
  • Fraser GA. (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience & Therapeutics, 15(1), 84–88.
  • Jetly R et al. (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology, 51, 585–588.
  • Kwee CMB et al. (2022). Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. European Neuropsychopharmacology, 59, 58–67.
  • Mammen G et al. (2018). Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. The Journal of Clinical Psychiatry, 79(4), 17r11839.
  • Marconi A et al. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269.
  • Masataka N. (2019). Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Frontiers in Psychology, 10, 2466.
  • Neumeister A et al. (2013). Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular Psychiatry, 18(9), 1034–1040.
  • Stoner SA. (2017). Effects of marijuana on mental health: Anxiety disorders. Alcohol & Drug Abuse Institute, University of Washington. Retrieved from adai.uw.edu.
  • Department of Medical Services, Ministry of Public Health, Thailand. (2024). Guidance on Cannabis for Medical Use, 6th edition.